Bringing Real Innovation to Medicare
Summary
The Centers for Medicare & Medicaid Services (CMS) is currently reviewing a new payment rule, which could impact coverage of innovative procedures like transcatheter aortic valve replacement for the treatment of severe aortic stenosis.
Please note: This is an archived post. Some of the information and data discussed in this article may be out of date. It is preserved here for historical reference but should not be used as the basis for business decisions. Please see our main Insights section for more recent posts.
At the same time, a recent study published in The New England Journal of Medicine has shown that transcatheter aortic valve replacement (TAVR) is safer and more effective than older ways of treating patients with open-heart surgery. Coverage decisions for TAVR and other breakthrough medical technologies were made under 2012 guidance, which tightly governed which physicians may utilize it.
In my latest Forbes article, I discuss the considerations that CMS may want to take when it comes to payment decisions for innovative treatments like TAVR.
To receive more Avalere updates, connect with us.
2025: Opportunity Through Uncertainty
Sign Up for Our 2025 Healthcare Industry Outlook Webinar
Register Now
January 23, 11 AM ET
Learn MoreServices
From beginning to end, our team synergy
produces measurable results. Let's work together.
produces measurable results. Let's work together.
